Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company, Tuesday announced positive top-line results from its Phase 2 VENTURE study of the oral tablet formulation of VK2735, the company's drug candidate for the treatment of obesity. The study met its primary goal.
In the study, participants receiving the oral tablet formulation of VK2735 showed statistically significant reductions in mean body weight of up to 12.2% from baseline and up to 10.9% compared to placebo. Further, the drug candidate was shown to be safe and well tolerated with mild to moderate treatment emergent adverse events.
VK2735 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.